Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, but for all of those commercialization pains, the drug has become an unexpected regulatory beacon for Pozen‘s (NASDAQ:POZN) latest drug candidate. PA32540 is Pozen’s safer aspirin, a compound drug that the Chapel Hill, North Carolina company developed for secondary prevention […]
Pozen (NASDAQ:POZN), now prepping to file a new drug application for its safer form of aspirin, has run into a slight regulatory headache. The company had looked on track way for a third-quarter drug filing on its combination aspirin product that targets the large market for cardiovascular disease prevention. Pozen even got its phase 3 […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Innovation is brewing in Chapel Hill, North Carolina. The University of North Carolina at Chapel Hill held its annual Emerging Company Showcase this week, an event that gives companies spun out of the university the chance to strut their stuff in an eight minute presentation before an audience of researchers, entrepreneurs and potential investors or […]
In prostate cancer treatment, newer might not necessarily be better. University of North Carolina at Chapel Hill research has found that intensity modulated radiation therapy, or IMRT, is as effective and produces fewer side effects than the newer and more expensive proton therapy. And IMRT is better than conventional radiation therapy for reducing side effects […]
Cempra (NASDAQ:CEMP) CEO Prabhavathi Fernandes speaks with urgency these days, particularly when discussing the antibiotics compounds her company plans for new drug applications in 2015. The Chapel Hill, North Carolina company spent last year seeking a large pharmaceutical company to take into late-stage development the two investigational antibiotics compounds treating drug-resistant bacteria. But Cempra ultimately […]
The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed in clinical trials that it causes fewer ulcers compared to aspirin alone. With those positive phase 3 clinical trial results in hand, Pozen now expects to file a new drug application on PA32540 in the third quarter. John Plachetka, CEO […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Kidney cancer research at the University of North Carolina at Chapel Hill is getting a funding boost from SAIC-Frederick with the goal of developing new treatments for renal cell carcinoma, the most common type of kidney cancer in adults. UNC’s Center for Integrative Chemical Biology and Drug Discovery (CICBDD) will receive $843,000 over 18 months […]
Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was intended to address that need. Backed by the marketing muscle of pharma giant AstraZeneca (NYSE:AZN), Pozen (NASDAQ:POZN), which developed the drug, had every expectation it […]
A new migraine treatment from pharmaceutical startup Achelios Therapeutics could enter clinical trials later this year, and it will be a new take on an older pain drug. The Chapel Hill, North Carolina company has raised $1.8 million out of a targeted $3 million first round of financing as the company launches operations and pursues […]
Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. PowerPoint presentations. After 11 minutes on stage, another presenter took their place. Immunotherapy company Heat Biologics broke from script and announced a $10 million series B round to complete one mid-stage study on its lead treatment candidate and two early […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
For a glimpse into social media’s coming role in pharmaceutical sales and marketing, and the digital health of tomorrow, consider its use in Gatorade’s marketing today. The Gatorade Company maintains a “mission control center” in the heart of the company’s marketing floor, said Bonin Bough, director of digital and social media for parent company PepsiCo […]
Duke University visits Chapel Hill tonight to play the University of North Carolina in a men’s college basketball matchup that will keep at least two-thirds of Research Triangle basketball fans riveted tonight. Even basketball observers outside of the Triangle call it the biggest rivalry in sports, or at least in college basketball. But the longtime […]
Antibiotics developer Cempra (NASDAQ:CEMP) is now a public company with an initial public offering raising close to $50 million. But to pull off an IPO, the Chapel Hill, North Carolina pharmaceutical company needed to cut the targeted share price in half and sell more shares than it intended. Today’s offering of 8.4 million shares was […]
Antibiotics developer Cempra Pharmaceuticals is one of three healthcare companies expected to go public this week. A total of eight initial public offerings are expected this week, according to Renaissance Capital, a Greenwich, Connecticut research firm specializing in initial public offerings. Besides Chapel Hill, North Carolina-based Cempra’s planned $86 million IPO, the other healthcare-related IPOs […]
As drug partnering auditions go, Pozen (NASDAQ:POZN) has played this role before: The small drug developer flirts with a large pharmaceutical company who has the resources and the reach to take its promising drug candidate global. Many companies audition without so much as a callback from Big Pharma. Chapel Hill, North Carolina-based Pozen has already […]